Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.28 +7.5%	$1.76	$0.91 ▼ $6.05	$190.87M	2.1	2.57 million shs	5.46 million shs
FTLF FitLife Brands	$12.81 +0.2%	$14.30	$9.83 ▼ $17.75	$120.30M	0.81	18,319 shs	426,066 shs
GLSI Greenwich LifeSciences	$8.99 +0.7%	$9.58	$8.06 ▼ $18.15	$120.18M	1.69	43,488 shs	83,487 shs
SCLX Scilex	$6.05 +14.2%	$4.99	$3.60 ▼ $78.05	$42.06M	1.13	67,948 shs	181,514 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	+7.55%	+2.70%	+21.93%	+82.40%	-52.60%
FTLF FitLife Brands	+0.16%	-3.83%	-10.92%	+1.59%	-23.52%
GLSI Greenwich LifeSciences	+0.67%	+1.01%	-7.51%	-12.04%	-47.43%
SCLX Scilex	+14.15%	+23.22%	+15.24%	-28.95%	-88.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDIT Editas Medicine	4.0506 of 5 stars	3.2	3.0	4.2	1.5	2.5	0.6
FTLF FitLife Brands	4.2861 of 5 stars	3.7	3.0	0.0	2.2	3.3	3.1
GLSI Greenwich LifeSciences	1.6968 of 5 stars	3.5	0.0	0.0	1.5	3.3	0.0
SCLX Scilex	2.2862 of 5 stars	3.3	2.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.31	Hold	$4.70	106.14% Upside
FTLF FitLife Brands	3.33	Buy	$20.50	60.03% Upside
GLSI Greenwich LifeSciences	3.00	Buy	$39.00	333.82% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	7,420.66% Upside

Current Analyst Ratings Breakdown

Latest SCLX, GLSI, FTLF, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
4/21/2025	GLSI Greenwich LifeSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $39.00
4/11/2025	SCLX Scilex	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/11/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/2/2025	SCLX Scilex	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$770.00 ➝ $630.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$32.31M	5.91	N/A	N/A	$1.63 per share	1.40
FTLF FitLife Brands	$64.47M	1.87	$1.01 per share	12.64	$3.93 per share	3.26
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
SCLX Scilex	$56.59M	0.74	N/A	N/A	($27.68) per share	-0.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
FTLF FitLife Brands	$8.98M	$0.84	15.25	11.65	N/A	13.85%	25.59%	15.26%	N/A
GLSI Greenwich LifeSciences	-$15.79M	-$1.26	N/A	N/A	N/A	N/A	-450.87%	-333.18%	8/12/2025 (Estimated)
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-146.93%	N/A	-82.65%	8/12/2025 (Estimated)

Latest SCLX, GLSI, FTLF, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	GLSI Greenwich LifeSciences	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
4/15/2025	Q4 2024	GLSI Greenwich LifeSciences	-$0.21	-$0.61	-$0.40	-$0.61	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	3.08	3.08
FTLF FitLife Brands	0.19	1.64	0.72
GLSI Greenwich LifeSciences	N/A	1.91	1.91
SCLX Scilex	N/A	0.10	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
FTLF FitLife Brands	2.32%
GLSI Greenwich LifeSciences	4.16%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	2.10%
FTLF FitLife Brands	61.30%
GLSI Greenwich LifeSciences	51.67%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable
FTLF FitLife Brands	20	9.39 million	3.63 million	Not Optionable
GLSI Greenwich LifeSciences	3	13.37 million	6.46 million	Not Optionable
SCLX Scilex	80	6.95 million	6.40 million	Optionable

SCLX, GLSI, FTLF, and EDIT Headlines

Recent News About These Companies

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...

June 25 at 11:29 AM | theglobeandmail.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23, 2025 | globenewswire.com

Scilex (NASDAQ:SCLX) Shares Down 3.1% - Time to Sell?

June 18, 2025 | americanbankingnews.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

Scilex Gets Orphan Drug Designation for Its Version of Colchicine

April 17, 2025 | marketwatch.com

Scilex treatment of pericarditis granted FDA orphan designation

April 17, 2025 | markets.businessinsider.com

Scilex confirms FDA awards orphan drug designation for colchicine

April 17, 2025 | markets.businessinsider.com

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

April 16, 2025 | globenewswire.com

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

April 15, 2025 | globenewswire.com

Scilex announces 1-for-35 reverse stock split

April 12, 2025 | markets.businessinsider.com

D. Boral Capital Downgrades Scilex Holding (SCLX)

April 12, 2025 | msn.com

Scilex downgraded to Hold from Buy at D. Boral Capital

April 11, 2025 | msn.com

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

April 11, 2025 | globenewswire.com

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

March 26, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLX, GLSI, FTLF, and EDIT Company Descriptions

Editas Medicine NASDAQ:EDIT

$2.28 +0.16 (+7.55%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.24 -0.04 (-1.75%)

As of 06/27/2025 07:55 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

FitLife Brands NASDAQ:FTLF

$12.81 +0.02 (+0.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.79 -0.02 (-0.16%)

As of 06/27/2025 05:50 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Greenwich LifeSciences NASDAQ:GLSI

$8.99 +0.06 (+0.67%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.94 -0.04 (-0.50%)

As of 06/27/2025 07:35 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Scilex NASDAQ:SCLX

$6.05 +0.75 (+14.15%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$6.06 +0.00 (+0.08%)

As of 06/27/2025 07:57 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time